Anti IL-1 β  

Immunohistochemistry of Human IL1 beta antibody. Tissue: human medullary lymph node. Fixation: formalin fixed paraffin embedded. Antigen retrieval: user optimized. Primary antibody: Human IL1 beta antibody. Secondary antibody: Peroxidase goat anti-rabbit at 1:10,000 for 45 min at RT. Localization: cytoplasm. Staining: Close up of medullary lymph node: positive staining in the cytoplasm of circulating macrophages. Neg Ctr (far right) of normal rabbit IgG with pH 6.2 at 40X.

Western Blot of Rabbit anti-Human IL-1s antibody. Lane 1: Human IL-1s. Load: 5 ng per lane. Primary antibody: Human IL-1s antibody at 1:2,000 for overnight at 4°C. Secondary antibody: Peroxidase rabbit secondary antibody at 1:40,000 for 30 min at RT. Block: Blocking Buffer for Fluorescent Western Blotting (MB-070) for 30 min at RT. Predicted/Observed size: 17 kDa, 17 kDa for Human IL-1s. Other band(s): Unspecific band at ~35 kDa.

HRPII activates an inflammatory pathway in human cerebral microvascular endothelial cells. (A) qRT-PCR of chemokine/cytokine mRNA levels of hCMEC/D3 cells treated with 25？μg HRPII or BSA for 8？h and 24？h. (B) TEER measurements for？in vitro？hCMEC/D3 barriers transfected with shRNAs for NFκB (N1 and N3) or a scrambled control (Scrb) for 36？h or incubated with inhibitors for NFκB, celastrol (Ce), and triptolide (tr) for 2？h prior to addition of HRPII (H; 10？μg). Data are mean values ± SEM of results from 6 to 8 replicates pooled from three independent experiments. ***,？P？< 0.0001 (by one-way ANOVA). (C) TEER measurements for？in vitro？barriers transfected with shRNAs to MyD88 (M1 and M3 and M5) or a scrambled control (Scrb) for 36？h prior to addition of recombinant purified HRPII (10？μg). Data are mean ± SEM of results from 6 to 8 replicates pooled from 3 independent experiments. ***,？P？< 0.0001 (by one-way ANOVA). Results of assessment of knockdown levels are shown in？Fig.？S2？in the supplemental material. (D) TEER measurements for？in vitro？barriers transfected with shRNAs for caspase-1 (C1 and C2) or a scrambled control (Scrb) for 36？h or with IL-1Ra (500？ng), anti-IL-1β (αIL-1β) (25？ng), or the caspase-1 inhibitor YVAD-CMK (80？μM) (C1 Inh) for 1？h prior to treatment with recombinant purified HRPII (10？μg; H). Data are mean values ± SEM of results from 6 to 8 replicates pooled from four independent experiments. ***,？P？< 0.001 (by one-way ANOVA); **,？P？< 0.05 (by one-way ANOVA). (E) Quantitative ELISA for cleaved IL-1β from cell lysates. Cells were treated for 24？h with HRPII (10？μg), LPS (3？μg/ml), or IFN-γ (100？ng/ml) or left untreated. Data represent results from three biological replicates, each performed in triplicate. *,？P？= 0.0002; **,？P？= 0.0005 (compared to untreated control by unpaired？t？test). Fig 3. PMID:？27273825

The effect of UK on the expressions of proinflammatory cytokines in LPS- stimulated BV-2？cells. Cells were pretreated with UK (125？nM, 250？nM, and 500？nM) for 12？h and with LPS (1000？ng/mL) treatment for another 12？h. The production of TNFα, PGE2, IL-6, and IL-1β？was measured by ELISA kits.？p？< 0.001 versus the control group,？？p？< 0.05 versus the LPS-stimulated group,？？？p？< 0.01 versus the control group, and？？？？p？< 0.001 versus the LPS-stimulated group,？n？=？3. Fig 2. PMID:？31428213

The effect of UK on the protein expressions of proinflammatory cytokines by western blot analysis. Cells were pretreated with UK (500？nM) for 12？h and with LPS (1000？ng/mL) treatment for another 12？h. The production of TNFα, IL-6, and IL-1β？was analyzed by western blot.？#p？< 0.05 versus the LPS-stimulated group,？？p？< 0.05 versus the control group, and？？？p？< 0.01 versus the control group,？n？=？3. Fig 3. PMID:？31428213